Amino acid derivative

NAC (N-Acetyl Cysteine)

The intravenous acetylcysteine label gives NAC a mean terminal half-life of 5.6 hours after a single intravenous dose, and the app lists 5.6 hours for oral use.1

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

NAC (N-Acetyl Cysteine) after one dose: 50% at ~5.6 h, 25% at 11.2 h, 12.5% at 16.8 h.

Drawn from the half-life in the app's model, ~5.6 h. The model's figures

NAC (N-acetylcysteine, also called acetylcysteine) is described on the Acetadote label as "the N-acetyl derivative of the naturally occurring amino acid, L-cysteine".1 The Acetadote label (Cumberland Pharmaceuticals, version 17, 2025) states that the product "is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen" in adults and pediatric patients who weigh 5 kg or greater.1 That product is an injection given into a vein, whereas the app's figures are for the oral route.1 In the United States, FDA states that NAC is excluded from the dietary supplement definition, and separately describes enforcement discretion for certain NAC products labeled as dietary supplements.2 The app grades the evidence for NAC as strong; that grade is the app's own, and the sections below give what each source reports, including trials with null main results.

2

How it works

The Acetadote label states that, after acetaminophen overdose, acetylcysteine "probably protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite of acetaminophen".1 The same label says acetylcysteine "is postulated to form cysteine and disulfides" and that "Cysteine is further metabolized to form glutathione and other metabolites".1

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~5.6 h
Bioavailability
9%
Typical dose
600–1200 mg/day
Route
Oral
Time to peak
~2 h

The second column of the table holds the app's figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-life~5.6 hMean terminal half-life of 5.6 hours after a single intravenous dose on the Acetadote label1; terminal half-life of total NAC 5.58 h after intravenous and 6.25 h after oral dosing in 6 healthy volunteers (Olsson 1988)3; late elimination half-life 2.27 h in 10 fasting healthy volunteers given a single 600 mg dose intravenously and as four oral formulations, with the route for this figure not stated in the source (Borgström 1986)4; mean 18.1 h (effervescent tablets) and 17.5 h (oral solution) after a single 11 g oral dose with sampling to 48 h (Greene 2016)5
Bioavailability9%Oral bioavailability of total NAC 9.1% and of reduced NAC 4.0% (Olsson 1988)3; oral availability between 6 and 10% across four oral formulations, lowest for the slow-release tablet and highest for the fast-dissolving tablet (Borgström 1986)4
Time to peak~2 hMean time of maximum concentration 2.12 h (effervescent tablets) and 1.89 h (oral solution) after a single 11 g oral dose in fasting healthy adults (Greene 2016)5
DistributionNot listed in the appSteady-state volume of distribution 0.47 liter/kg and protein binding of 66 to 87% after intravenous dosing (Acetadote label)1; volume of distribution 0.47 l/kg for total NAC and 0.59 l/kg for reduced NAC (Olsson 1988)3; volume of distribution 0.33 l/kg (Borgström 1986)4

The label figure matches the app's 5.6 hours, but it is for a single intravenous dose of total acetylcysteine, not an oral dose.1 The half-life depends on which form is measured: Olsson and colleagues report a terminal half-life of 1.95 h for reduced NAC after intravenous dosing, against 5.58 h for total NAC.3 The 17.5 to 18.1 h figures in Greene and colleagues come from a much larger single oral dose (11 g) and longer sampling (48 h) than the 400 to 600 mg doses and 12 to 30 h sampling in the older studies, and the sources do not explain the difference.5,3,4

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: twice daily (600 mg tablet, PANTHEON)7, once daily (600 mg, BRONCUS)6.

An illustration from a pharmacokinetic model using a half-life of 5.6 hours. It is not a measured level or a suggested dose.

4

Human studies

Table 4.1Human studies10 rows
Study and yearDesignPeopleDose and lengthMain result
Olsson and colleagues, Eur J Clin Pharmacol 19883Randomized cross-over pharmacokinetic study; authors from ACO Läkemedel AB, Solna, Sweden6 healthy volunteersNAC 200 mg intravenous and 400 mg oral; samples for 30 hTerminal half-life of total NAC 5.58 h intravenous and 6.25 h oral; oral bioavailability 9.1% (total NAC) and 4.0% (reduced NAC)3
Borgström and colleagues, Eur J Clin Pharmacol 19864Single-dose comparison of intravenous NAC with three fast-dissolving and one slow-release oral formulation10 fasting healthy volunteers (5 men, 5 women)Single 600 mg dose; samples for 12 hLate elimination half-life 2.27 h; oral availability 6 to 10%4
Greene and colleagues, Curr Ther Res 20165Open-label, randomized, single-dose, crossover; funded by Arbor Pharmaceuticals30 healthy adults (25 male, 5 female)Single 11 g oral dose, effervescent tablets and oral solution, 7-day washout; 48 h samplingMean Cmax 26.5 µg/mL (effervescent tablets) and 28.4 µg/mL (oral solution); relative bioavailability 94.0% (SD 18.5); products bioequivalent; at least one adverse event in 14 of 29 (48.3%) and 15 of 30 (50.0%), none serious5
Decramer and colleagues (BRONCUS), Lancet 20056Randomised placebo-controlled, 50 centres, intention to treat523 patients with COPD600 mg daily or placebo; 3 yearsFEV1 decline 54 mL vs 47 mL per year; exacerbations per year 1.25 vs 1.29 (hazard ratio 0.99, 95% CI 0.89-1.10, p=0.85)6
Zheng and colleagues (PANTHEON), Lancet Respir Med 20147Randomised, double-blind, placebo-controlled, 34 hospitals in China; funded by Hainan Zambon Pharmaceutical1006 randomised (504 NAC, 502 placebo); ages 40-80, moderate-to-severe COPDOne 600 mg tablet twice daily or placebo; 1 year1·16 vs 1·49 exacerbations per patient-year in 482 analysed patients per group (risk ratio 0·78, 95% CI 0·67-0·90; p=0·0011); adverse events 146 (29%) of 495 vs 130 (26%) of 495, of which 48 vs 46 serious7
Zhou and colleagues, Nat Commun 20248Multicentre, randomised, double-blind, placebo-controlled, 24 centres in China968 randomised, mild-to-moderate COPD (GOLD stage 1-2)600 mg twice daily or placebo; 2 yearsCoprimary outcomes, neither significant: total exacerbations 0.65 vs 0.72 per patient-year (RR 0.90, 95% CI 0.80-1.02, P = 0.10); FEV1 before bronchodilator at 24 months 137 ml vs 121 ml (difference 16 ml, 95% CI -69 to 100, P = 0.72); secondary, not adjusted for multiple comparisons: moderate or severe exacerbations 0.34 vs 0.45 per patient-year (RR 0.76)8
Poole and colleagues, Cochrane Database Syst Rev 20199Systematic review of oral mucolytic agents against placebo; NAC was the mucolytic in 21 studies, and others included carbocysteine, erdosteine and ambroxol38 trials, 10,377 participants with chronic bronchitis or COPDGiven at least once daily; studies lasted two months to three yearsExacerbation-free: Peto odds ratio 1.73 (95% CI 1.56 to 1.91; 28 studies, 6723 participants; moderate-certainty evidence), with high heterogeneity (I² = 62%) and smaller benefit in more recent studies than in earlier ones; mortality Peto OR 0.98 (95% CI 0.51 to 1.87; 11 studies, 3527 participants); pooled across mucolytics, not NAC alone9
IPF Clinical Research Network (Raghu), N Engl J Med 201210Randomized, double-blind, placebo-controlled; three-drug arm (prednisone, azathioprine, NAC) stopped earlyIdiopathic pulmonary fibrosis, mild-to-moderate impairment; 77 combination, 78 placebo at interimThree-drug combination or placebo; 60-week plan, mean follow-up 32 weeks at terminationCombination arm: death 8 vs 1 (P=0.01), hospitalization 23 vs 7; NAC-only comparison not reported in that paper10
IPF Clinical Research Network (Martinez), N Engl J Med 201411Randomized, double-blind, placebo-controlled; NAC against placebo after the three-drug arm was stopped; funded by the National Heart, Lung, and Blood InstituteIdiopathic pulmonary fibrosis, mild-to-moderate impairment; 133 NAC, 131 placeboNAC 600 mg three times daily or placebo; 60 weeksFVC change -0.18 liters vs -0.19 liters (P=0.77); death 4.9% vs 2.5% (P=0.30); serious cardiac disorders 6.8% vs 1.5% (P=0.033); serious gastrointestinal disorders 0% vs 4.6% (P=0.014)11
Gray and colleagues, Drug Alcohol Depend 201712Double-blind, randomized, placebo-controlled, six clinical sites; supported by the National Institutes of Health302 treatment-seeking adults aged 18-50 with cannabis use disorderNAC 1200 mg or placebo twice daily, plus contingency management; 12 weeksOdds of a negative urine cannabinoid test: odds ratio 1.00 (95% CI 0.63-1.59, p=0.984); 22.3% vs 22.4% of tests negative12

Deeper analysis: Greene and colleagues, 11 g bioavailability study (2016)

Greene and colleagues reported a single-center, open-label, randomized, single-dose crossover study in Current Therapeutic Research in 2016, comparing effervescent NAC tablets with an oral solution in fasting healthy adults.5 Thirty adults were enrolled (mean age 35.2 years), 29 completed both periods, and the measured quantity was total plasma NAC by LC-MS/MS over 48 hours.5 The two products were bioequivalent on the prespecified parameters, and the apparent terminal half-life was 18.1 h for tablets and 17.5 h for solution against the app's 5.6 hours.5 Nausea was reported by 4 (13.8%) with tablets and 3 (10.0%) with solution, diarrhea by 6 (20.7%) and 6 (20.0%), and the authors write that "All TEAEs were considered to be mild in intensity".5 One participant withdrew after the first period with a nonserious TEAE the authors describe as "syncope and seizure-like activity" occurring more than 24 hours after the oral solution dose.5 The authors name these limitations: "Data were obtained from a small number of healthy adult subjects, under fasting conditions, after administration of a single 11-g dose of NAC", and, because it was a single-dose study, "meaningful safety-profile conclusions cannot be drawn from small differences between the treatments".5 Arbor Pharmaceuticals funded the study and, in the authors' words, "was actively involved in the study design, assurance of the accuracy of the data collection and analysis, and interpretation of data"; the tablet studied (Cetylev) is an Arbor product, and editorial support was paid for by the sponsor.5 The authors report "no other conflicts of interest regarding the content of this article".5

Deeper analysis: PANTHEON, twice-daily 600 mg in moderate-to-severe COPD (2014)

Zheng and colleagues (Guangzhou Institute of Respiratory Disease) reported PANTHEON in The Lancet Respiratory Medicine in 2014 from 34 hospitals in China, in patients aged 40-80 years with moderate-to-severe COPD.7 Patients were randomly allocated to one 600 mg tablet of N-acetylcysteine or matched placebo twice daily for 1 year, and the primary endpoint was the annual exacerbation rate.7 Of 1006 randomised (504 N-acetylcysteine, 502 placebo), the analysis covered patients who received at least one dose and had at least one assessment visit: 497 exacerbations in 482 patients on N-acetylcysteine (1·16 per patient-year) and 641 in 482 on placebo (1·49 per patient-year; risk ratio 0·78, 95% CI 0·67-0·90; p=0·0011).7 Adverse events occurred in 146 (29%) of 495 patients on N-acetylcysteine (48 serious) and 130 (26%) of 495 on placebo (46 serious).7 The record names Hainan Zambon Pharmaceutical as funder and lists Zambon affiliations for three authors (Li Xia in Beijing; Raiteri and Sardina in Milan).7 The PubMed record gives a summary only, so the authors' limitations section and any further null results are not reported here.

Deeper analysis: Zhou and colleagues, high-dose NAC in mild-to-moderate COPD (2024)

Zhou and colleagues (Guangzhou Institute of Respiratory Health, Guangzhou Medical University) reported a multicentre trial in Nature Communications in 2024, in which 968 patients with mild-to-moderate COPD were randomly assigned to N-acetylcysteine 600 mg twice daily or matched placebo for two years.8 The coprimary outcomes were the annual rate of total exacerbations and the change from baseline to 24 months in FEV1 before bronchodilator use, and neither showed a significant difference: total exacerbations were 0.65 vs 0.72 per patient-year (RR 0.90, 95% CI 0.80-1.02, P = 0.10) and FEV1 before bronchodilator at 24 months differed by 16 ml, which the authors report as not significant.8 The annual rate of moderate or severe exacerbations, a secondary outcome, was 0.34 vs 0.45 per patient-year (RR 0.76), and the authors state that secondary and subgroup analyses are exploratory and were not adjusted for multiple comparisons.8 Adverse events occurred in 117 events among 464 patients (25.2%) on N-acetylcysteine and 98 among 464 (21.1%) on placebo (P = 0.16), serious adverse events in 40 (8.6%) and 31 (6.7%) (P = 0.32), and eight patients died, three on N-acetylcysteine and five on placebo, none judged by the investigators to be related to the study medication.8 The authors list limitations including a lower proportion of females than among Chinese patients with mild-to-moderate COPD, and that the trial "may have been underpowered to detect the effect of N-acetylcysteine on lung function".8 Zhejiang Jinhua Pharmaceutical manufactured and provided the N-acetylcysteine and placebo, and the authors state that this company and the funding providers "had no role in the study design, implementation, monitoring, statistical analysis, interpretation, writing, and publication of the manuscript".8 All authors declare "no financial relationships with any organizations that might have an interest in the submitted work in the previous three years".8

Deeper analysis: BRONCUS, 600 mg daily in COPD (2005)

Decramer and colleagues reported BRONCUS in The Lancet in 2005, with FEV1 decline and exacerbations per year as primary outcomes.6 Neither primary outcome differed: FEV1 declined by 54 mL (SE 6) against 47 mL (6) a year, and exacerbations were 1.25 (SD 1.35) against 1.29 (SD 1.46) a year (hazard ratio 0.99, 95% CI 0.89-1.10, p=0.85).6 A subgroup analysis "suggested that the exacerbation rate might be reduced with N acetylcysteine in patients not treated with inhaled corticosteroids", and the authors concluded that N-acetylcysteine "is ineffective at prevention of deterioration in lung function and prevention of exacerbations in patients with COPD".6 The same summary reports that a secondary analysis "was suggestive of an effect on hyperinflation".6 The PubMed record gives a summary only, with no funding statement, limitations or adverse event data.

Deeper analysis: PANTHER-IPF, NAC in idiopathic pulmonary fibrosis (2012 and 2014)

The Idiopathic Pulmonary Fibrosis Clinical Research Network began a three-arm trial (prednisone, azathioprine and NAC; NAC alone; placebo), and at a planned interim analysis the combination group had an increased rate of death (8 vs 1, P=0.01) and hospitalization (23 vs 7) compared with placebo, and the monitoring board recommended ending that group; the 2012 paper did not report the NAC-only comparison.10 The 2012 paper reports grants from the NHLBI and the Cowlin Family Fund at the Chicago Community Trust, and states that NAC and matching placebo were donated by Zambon.10 The trial continued as a two-group comparison of NAC and placebo, and in the 2014 paper 105 more patients were randomized after the combination arm ended.11 At 60 weeks there was "no significant difference in the change in FVC" between groups (-0.18 liters and -0.19 liters; P=0.77), and deaths were 4.9% against 2.5% (P=0.30 by the log-rank test) with acute exacerbation 2.3% in each group.11 Medication was discontinued in 34 of 133 patients on NAC and 29 of 131 on placebo (p=0.53).11 Serious cardiac disorders occurred in 6.8 percent on NAC (9 of 133) against 1.5 percent on placebo (2 of 133) (P=0.033), and serious gastrointestinal disorders in 0 percent against 4.6 percent (6 of 133) (P=0.014).11 The authors write that their results "are applicable only to IPF patients who met the inclusion and exclusion criteria of this trial".11 The 2014 paper states that the National Heart, Lung, and Blood Institute and the Cowlin Family Fund funded the network, that "NAC and matching placebo were a gift from Zambon S.p.A.", and that "Zambon reviewed and provided comments on a draft of the manuscript before submission for publication; as a result minor changes were made".11

Deeper analysis: Gray and colleagues, NAC for cannabis use disorder in adults (2017)

Gray and colleagues reported in Drug and Alcohol Dependence in 2017 a 12-week trial at six clinical sites of the National Drug Abuse Treatment Clinical Trials Network, in which 302 treatment-seeking adults aged 18-50 with cannabis use disorder were randomized to NAC 1200 mg (n=153) or placebo (n=149) twice daily, all with contingency management.12 The primary measure was the odds of negative urine cannabinoid tests, and the authors report "not statistically significant evidence that the NAC and placebo groups differed in cannabis abstinence" (odds ratio=1.00, 95% confidence interval 0.63-1.59, p=0.984), with 22.3% of tests negative on NAC and 22.4% on placebo.12 Any treatment-emergent adverse event was reported by 26.8% of participants on NAC and 34.2% on placebo, and of 7 serious adverse events, 6 occurred on placebo and 1 on NAC, none judged causally related to the study medication.12 Only a small subset met the prespecified adherence criteria (n=31 on NAC and n=26 on placebo), and the authors state that "medication adherence was poorer than in the prior adolescent trial, notably compromising the potential to test for efficacy in adults".12 The study was supported by National Institutes of Health grants, and the authors state the funders "had no role in the design and conduct of the study"; the disclosure statement lists research support or consulting from several companies for some authors, none of which it ties to NAC.12

The app's typical dose is 600–1200 mg/day by the oral route; the table gives what each source reports.

Table 5.1Doses reported in studies and on labels7 rows
SettingDose, route and lengthReference
Acetadote label, infusion-rate study in acetaminophen poisoning150 mg/kg intravenous loading dose, given over 15 or 60 minutesAcetadote label1
Greene 2016, healthy adults, n=3011 g single oral dose, tablets dissolved in water or oral solutionGreene 20165
BRONCUS, COPD, n=523600 mg daily, 3 years (route not stated in the PubMed record)Decramer 20056
PANTHEON, moderate-to-severe COPD, n=1006 randomisedOne 600 mg tablet twice daily, 1 yearZheng 20147
Zhou 2024, mild-to-moderate COPD, n=968 randomised600 mg twice daily, 2 yearsZhou 20248
PANTHER-IPF, idiopathic pulmonary fibrosis, NAC n=133NAC 600 mg three times daily, 60 weeksIPF Clinical Research Network 201411
Gray 2017, cannabis use disorder, NAC n=1531200 mg twice daily, 12 weeks, plus contingency managementGray 201712
  • The Acetadote label lists the most common adverse reactions (those above 2%) after intravenous use as rash, urticaria/facial flushing and pruritus.1
  • The label states that serious acute hypersensitivity reactions, including fatal or life-threatening anaphylaxis, "have been observed in patients receiving intravenous acetylcysteine for acetaminophen overdose", and that intravenous administration "can cause fluid overload, potentially resulting in hyponatremia, seizure, and death".1
  • After a single 11 g oral dose in healthy adults, the most common events included diarrhea, flatulence, nausea, dysgeusia and upper abdominal pain, and no serious adverse events were reported.5
  • In PANTHER-IPF, serious cardiac disorders were more frequent on NAC (6.8 percent against 1.5 percent) and serious gastrointestinal disorders less frequent (0 percent against 4.6 percent).11
  • On pregnancy, the label states that "Limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk".1

The Acetadote label is for an intravenous injection indicated for acetaminophen overdose in adults and in pediatric patients who weigh 5 kg or greater.1 FDA's 2022 guidance states that NAC "is excluded from the dietary supplement definition" because NAC was approved as a new drug on September 14, 1963, and FDA states it is not aware of any evidence that NAC was marketed as a dietary supplement or as a food before that date.2 It states an intent to exercise enforcement discretion for certain NAC products labeled as dietary supplements, but not for an NAC product labeled as a dietary supplement that is intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease.2 The guidance states that FDA is considering initiating rulemaking to permit the use of NAC in or as a dietary supplement, and that the full safety review remains ongoing.2 The text of the World Anti-Doping Agency's 2026 Prohibited List that was searched has no entry naming acetylcysteine, N-acetylcysteine or cysteine.13 The list's S0 class covers pharmacological substances not addressed by the later sections of the List and "with no current approval by any governmental regulatory health" authority for human therapeutic use.13

8

Storage and handling

The Acetadote label states: "Store unopened vials at controlled room temperature, 20° to 25°C (68° to 77°F)"; this applies to the intravenous product, and the sources gathered here give no storage statement for oral NAC products.1

The app lists a duration of 12 hours; the label and the three pharmacokinetic papers read report concentration-time results and half-lives rather than a duration of activity. Reported half-lives range from 1.95 h (reduced NAC, intravenous) to 18.1 h (total NAC after 11 g orally) across the studies, and the sources do not give a single oral figure at the app's 600 to 1200 mg per day.3,5 The Cochrane review's authors state that mucolytic results on mortality are "too imprecise to be certain whether or not there is an effect".9 The 2017 cannabis trial's authors state that NAC had not been tested in cannabis use disorder in a randomized placebo-controlled trial without contingency management.12

What is the half-life of NAC?

The Acetadote label gives a mean terminal half-life of 5.6 hours after a single intravenous dose, and the app lists about 5.6 hours.1 Olsson and colleagues reported 6.25 hours after an oral 400 mg dose of total NAC in 6 healthy volunteers, and Greene and colleagues reported mean half-lives of 18.1 and 17.5 hours after a single 11 g oral dose.3,5

What is the oral bioavailability of NAC?

Olsson and colleagues reported an oral bioavailability of 9.1% for total NAC, and the app lists 9%.3 The same study reported 4.0% for reduced NAC, and Borgström and colleagues reported oral availability between 6 and 10% across four oral formulations.3,4

How long does NAC take to reach its peak level?

Greene and colleagues reported mean times to maximum concentration of 2.12 hours (effervescent tablets) and 1.89 hours (oral solution) after a single 11 g oral dose in fasting healthy adults, and the app lists about 2 hours.5

Is NAC banned by WADA?

The text of the WADA 2026 Prohibited List that was searched has no entry naming acetylcysteine, N-acetylcysteine or cysteine.13

Is NAC a dietary supplement in the United States?

FDA states that NAC is excluded from the dietary supplement definition under section 201(ff)(3)(B)(i) of the FD&C Act.2 It also states an intent to exercise enforcement discretion for certain NAC products labeled as dietary supplements.2

Did NAC reduce COPD exacerbations in trials?

The trials reported different results: PANTHEON (600 mg twice daily, 1 year) reported fewer exacerbations on NAC, while the 2024 trial (600 mg twice daily, 2 years) reported a difference in total exacerbations that did not reach statistical significance and BRONCUS (600 mg daily, 3 years) reported no difference.7,8,6 PANTHEON (1006 randomised) reported 1·16 against 1·49 exacerbations per patient-year (risk ratio 0·78, 95% CI 0·67-0·90).7 PANTHEON was funded by Hainan Zambon Pharmaceutical, and three of its authors list Zambon affiliations.7 BRONCUS (523 patients) reported 1.25 against 1.29 per year (hazard ratio 0.99, 95% CI 0.89-1.10), and the 2024 trial of 968 patients reported 0.65 against 0.72 per patient-year for total exacerbations (RR 0.90, 95% CI 0.80-1.02, P = 0.10).6,8

Did NAC change lung function in idiopathic pulmonary fibrosis?

In the PANTHER-IPF comparison of NAC with placebo, the change in forced vital capacity at 60 weeks was -0.18 liters on NAC and -0.19 liters on placebo, with no significant difference (P=0.77).11 In the same comparison, death was 4.9% on NAC against 2.5% on placebo (P=0.30 by the log-rank test), and serious cardiac disorders occurred in 6.8 percent against 1.5 percent (P=0.033).11 Its authors state the results apply only to patients who met its inclusion and exclusion criteria.11

What side effects of NAC have been reported?

The Acetadote label lists rash, urticaria/facial flushing and pruritus as the most common adverse reactions after intravenous use.1 The same label states that serious acute hypersensitivity reactions, including fatal or life-threatening anaphylaxis, have been observed in patients receiving intravenous acetylcysteine for acetaminophen overdose.1 After a single 11 g oral dose in healthy adults the most common events included diarrhea, flatulence, nausea, dysgeusia and upper abdominal pain, with no serious adverse events reported,5 and in PANTHER-IPF serious cardiac disorders were more frequent on NAC (6.8 percent against 1.5 percent) and serious gastrointestinal disorders less frequent (0 percent against 4.6 percent).11

12

References

  1. Cumberland Pharmaceuticals. Acetadote (acetylcysteine) injection, solution. US prescribing information, DailyMed label version 17, 2025. DailyMed label
  2. US Food and Drug Administration. Policy Regarding N-acetyl-L-cysteine: Guidance for Industry. August 2022. FDA guidance
  3. Olsson B, et al. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 1988. PMID 3360052
  4. Borgström L, et al. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 1986. PMID 3803419
  5. Greene SC, et al. Effervescent N-Acetylcysteine Tablets versus Oral Solution N-Acetylcysteine in Fasting Healthy Adults: An Open-Label, Randomized, Single-Dose, Crossover, Relative Bioavailability Study. Curr Ther Res Clin Exp 2016. PMID 27668024
  6. Decramer M, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (BRONCUS): a randomised placebo-controlled trial. Lancet 2005. PMID 15866309
  7. Zheng JP, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2014. PMID 24621680
  8. Zhou Y, et al. Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial. Nat Commun 2024. PMID 39349461
  9. Poole P, et al. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2019. PMID 31107966
  10. Idiopathic Pulmonary Fibrosis Clinical Research Network, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012. PMID 22607134
  11. Idiopathic Pulmonary Fibrosis Clinical Research Network, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014. PMID 24836309
  12. Gray KM, et al. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend 2017. PMID 28623823
  13. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list